Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is designed for solution that includes information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Pulmonx Corporation

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Hold rating on Pulmonx, with a price target of $3.00. The company’s s...

Current Quarter	$-0.39	Next Quarter	$-0.33
Current Year	$-1.47	Next Year	$-1.28
QoQ Growth	+15.4%	YoY Growth	+12.9%
3Y EPS CAGR	-2.2%	Target Price	$5.75
Consensus	Buy	Upside	+127.3%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	LUNG	$2.53	+0.80%	1.03M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	LUNG	$2.53	+0.8%	1.03M
3
4
5
6

LUNG

LUNG

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Pulmonx Corporation Data in Excel

Get Pulmonx Corporation Data in Excel